A Rapid and Sensitive Method for Measuring N-Acetylglucosaminidase Activity in Cultured Cells

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Mauri, Victor ^a   Lotfi, Parisa ^a   Segatori, Laura ^b   Sardiello, Marco ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b RICE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLGLUCOSAMINIDASE; METHYLUMBELLIFERYL 2 ACETAMIDO 2 DEOXY ALPHA DEXTRO GLUCOPYRANOSIDE; REAGENT; SUCROSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EB; UNCLASSIFIED DRUG;

ARTICLE; CELL ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; FIBROBLAST; GENE; HUMAN; HUMAN CELL; LYSOSOME; NAGLU GENE; REPRODUCIBILITY; SANFILIPPO SYNDROME; SENSITIVITY AND SPECIFICITY;

ACETYLGLUCOSAMINIDASE; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BIOLOGICAL ASSAY; CELLS, CULTURED; FIBROBLASTS; HUMANS; LYSOSOMES; MUCOPOLYSACCHARIDOSIS III; MUTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84879516834     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068060     Document Type: Article

References (80)

1. Valstar MJ, Ruijter GJG, Diggelen OP, Poorthuis BJ, Wijburg FA, (2008) Sanfilippo syndrome: A mini-review. Journal of Inherited Metabolic Disease 31: 240-252.
2. Li HH, Zhao HZ, Neufeld EF, Cai Y, Gomez-Pinilla F, (2002) Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B. Journal of neuroscience research. 69: 30-38.
3. Heldermon CD, Hennig AK, Ohlemiller KK, Ogilvie JM, Herzog ED, et al. (2007) Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B. PloS one. 2: e772.
4. Walkley SU, (2009) Pathogenic cascades in lysosomal disease-Why so complex? Journal of inherited metabolic disease 32: 181-189.
5. de Ruijter J, Valstar MJ, Wijburg FA, (2011) Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies. Current pharmaceutical biotechnology 12: 923-930.
6. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, et al. (2008) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. European journal of pediatrics 167: 267-277.
7. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, et al. (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. The New England journal of medicine. 344: 182-188.
8. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, et al. (2004) Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). The Journal of pediatrics 144: 574-580.
9. Auclair D, Finnie J, White J, Nielsen T, Fuller M, et al. (2010) Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Molecular genetics and metabolism 99: 132-141.
10. Munoz-Rojas MV, Vieira T, Costa R, Fagondes S, John A, et al. (2008) Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. American journal of medical genetics Part A 146A: 2538-2544.
11. Huynh HT, Grubb JH, Vogler C, Sly WS, (2012) Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII. Proceedings of the National Academy of Sciences of the United States of America 109: 17022-17027.
12. Platt FM, Jeyakumar M, (2008) Substrate reduction therapy. Acta paediatrica 97: 88-93.
13. Jakobkiewicz-Banecka J, Wegrzyn A, Wegrzyn G, (2007) Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. Journal of applied genetics 48: 383-388.
14. Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, et al. (2004) alpha-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. Journal of molecular biology 338: 453-462.
15. Linde L, Kerem B, (2008) Introducing sense into nonsense in treatments of human genetic diseases. Trends in genetics: TIG 24: 552-563.
16. Valayannopoulos V, Wijburg FA, (2011) Therapy for the mucopolysaccharidoses. Rheumatology 50Suppl 5: v49-59.
17. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, et al. (2002) Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Molecular therapy: the journal of the American Society of Gene Therapy 5: 42-49.
18. Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, et al. (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Molecular therapy: the journal of the American Society of Gene Therapy 19: 251-259.
19. Cressant A, Desmaris N, Verot L, Brejot T, Froissart R, et al. (2004) Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. The Journal of neuroscience: the official journal of the Society for Neuroscience 24: 10229-10239.
20. Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, et al. (2009) A gene network regulating lysosomal biogenesis and function. Science 325: 473-477.
21. Sardiello M, Ballabio A, (2009) Lysosomal enhancement: a CLEAR answer to cellular degradative needs. Cell cycle 8: 4021-4022.
22. Schultz ML, Tecedor L, Chang M, Davidson BL, (2011) Clarifying lysosomal storage diseases. Trends in neurosciences 34: 401-410.
23. Medina DL, Fraldi A, Bouche V, Annunziata F, Mansueto G, et al. (2011) Transcriptional activation of lysosomal exocytosis promotes cellular clearance. Developmental cell 21: 421-430.
24. Tsunemi T, Ashe TD, Morrison BE, Soriano KR, Au J, et al. (2012) PGC-1alpha rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function. Science translational medicine 4: 142ra197.
25. Parr C, Carzaniga R, Gentleman SM, Van Leuven F, Walter J, et al. (2012) Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein. Molecular and cellular biology 32: 4410-4418.
26. Song W, Wang F, Savini M, Ake A, di Ronza A, et al. (2013) TFEB regulates lysosomal proteostasis. Human molecular genetics.
27. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, et al. (2010) Pathogenic lysosomal depletion in Parkinson's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 30: 12535-12544.
28. Beesley CE, Jackson M, Young EP, Vellodi A, Winchester BG, (2005) Molecular defects in Sanfilippo syndrome type B (mucopolysaccharidosis IIIB). Journal of inherited metabolic disease 28: 759-767.
29. Beesley C, Moraitou M, Winchester B, Schulpis K, Dimitriou E, et al. (2004) Sanfilippo B syndrome: molecular defects in Greek patients. Clinical genetics 65: 143-149.
30. Tessitore A, Villani GR, Di Domenico C, Filocamo M, Gatti R, et al. (2000) Molecular defects in the alpha-N-acetylglucosaminidase gene in Italian Sanfilippo type B patients. Human genetics 107: 568-576.
31. Heron B, Mikaeloff Y, Froissart R, Caridade G, Maire I, et al. (2011) Incidence and natural history of mucopolysaccharidosis type III in France and comparison with United Kingdom and Greece. American journal of medical genetics Part A 155A: 58-68.
32. Neufeld EF, (1991) Lysosomal storage diseases. Annual review of biochemistry 60: 257-280.
33. Gieselmann V, (1995) Lysosomal storage diseases. Biochimica et biophysica acta 1270: 103-136.
34. Durand P, Fabrega S, Henrissat B, Mornon JP, Lehn P, (2000) Structural features of normal and mutant human lysosomal glycoside hydrolases deduced from bioinformatics analysis. Human molecular genetics 9: 967-977.
35. Ellgaard L, Helenius A, (2003) Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4: 181-191.
36. Wang F, Song W, Brancati G, Segatori L, (2011) Inhibition of endoplasmic reticulum-associated degradation rescues native folding in loss of function protein misfolding diseases. The Journal of biological chemistry 286: 43454-43464.
37. Parenti G, (2009) Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO molecular medicine 1: 268-279.
38. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, et al. (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America 99: 15428-15433.
39. Mu TW, Ong DS, Wang YJ, Balch WE, Yates JR III, et al. (2008) Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134: 769-781.
40. Valenzano KJ, Khanna R, Powe AC, Boyd R, Lee G, et al. (2011) Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay and drug development technologies 9: 213-235.
41. Fan JQ, Ishii S, (2007) Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J 274: 4962-4971.
42. Maegawa GH, Tropak M, Buttner J, Stockley T, Kok F, et al. (2007) Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis. J Biol Chem 282: 9150-9161.
43. Maegawa GH, Tropak MB, Buttner JD, Rigat BA, Fuller M, et al. (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 284: 23502-23516.
44. Tropak MB, Blanchard JE, Withers SG, Brown ED, Mahuran D, (2007) High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones. Chem Biol 14: 153-164.
45. Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, et al. (2007) Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci U S A 104: 13192-13197.
46. Urban DJ, Zheng W, Goker-Alpan O, Jadhav A, Lamarca ME, et al. (2008) Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening. Comb Chem High Throughput Screen 11: 817-824.
47. O'Brien JS, (1972) Sanfilippo syndrome: profound deficiency of alpha-acetylglucosaminidase activity in organs and skin fibroblasts from type-B patients. Proc Natl Acad Sci U S A 69: 1720-1722.
48. Chow P, Weissmann B, (1981) 4-Methylumbelliferyl 2-acetamido-2-deoxy-alpha-D-glucopyranoside, a fluorogenic substrate for N-acetyl-alpha-D-glucosaminidase. Carbohydrate research 96: 87-93.
49. Marsh J, Fensom AH, (1985) 4-Methylumbelliferyl alpha-N-acetylglucosaminidase activity for diagnosis of Sanfilippo B disease. Clinical genetics 27: 258-262.
50. Gerber SA, Turecek F, Gelb MH, (2001) Design and synthesis of substrate and internal standard conjugates for profiling enzyme activity in the Sanfilippo syndrome by affinity chromatography/electrospray ionization mass spectrometry. Bioconjugate chemistry 12: 603-615.
51. Gerber SA, Scott CR, Turecek F, Gelb MH, (2001) Direct profiling of multiple enzyme activities in human cell lysates by affinity chromatography/electrospray ionization mass spectrometry: application to clinical enzymology. Analytical chemistry 73: 1651-1657.
52. Wolfe BJ, Ghomashchi F, Kim T, Abam CA, Sadilek M, et al. (2012) New substrates and enzyme assays for the detection of mucopolysaccharidosis III (Sanfilippo Syndrome) types A, B, C, and D by tandem mass spectrometry. Bioconjugate chemistry 23: 557-564.
53. Hopwood JJ, Elliott H, (1982) Detection of the Sanfilippo type B syndrome using radiolabelled oligosaccharides as substrates for the estimation of alpha-N-acetylglucosaminidase. Clin Chim Acta 120: 77-86.
54. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of biomolecular screening 4: 67-73.
55. Okada S, Veath ML, Leroy J, O'Brien JS, (1971) Ganglioside GM2 storage diseases: hexosaminidase deficiencies in cultured fibroblasts. American journal of human genetics 23: 55-61.
56. Schmidtchen A, Greenberg D, Zhao HG, Li HH, Huang Y, et al. (1998) NAGLU mutations underlying Sanfilippo syndrome type B. American journal of human genetics. 62: 64-69.
57. Lee-Chen GJ, Lin SP, Lin SZ, Chuang CK, Hsiao KT, et al. (2002) Identification and characterisation of mutations underlying Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). Journal of medical genetics 39: E3.
58. Beesley CE, Young EP, Vellodi A, Winchester BG, (1998) Identification of 12 novel mutations in the alpha-N-acetylglucosaminidase gene in 14 patients with Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB). Journal of medical genetics 35: 910-914.
59. Butterworth J, (1978) Diagnosis of the mucopolysaccharidoses using cultured skin fibroblasts and amniotic fluid cells. Journal of inherited metabolic disease 1: 25-28.
60. Palmieri M, Impey S, Kang H, di Ronza A, Pelz C, et al. (2011) Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Human molecular genetics 20: 3852-3866.
61. Brooks DA, Muller VJ, Hopwood JJ, (2006) Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends in molecular medicine 12: 367-373.
62. Sarkar C, Zhang Z, Mukherjee AB, (2011) Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Molecular genetics and metabolism 104: 338-345.
63. Fan JQ, Ishii S, Asano N, Suzuki Y, (1999) Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 5: 112-115.
64. Matsuda J, Suzuki O, Oshima A, Yamamoto Y, Noguchi A, et al. (2003) Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis. Proc Natl Acad Sci U S A 100: 15912-15917.
65. Okumiya T, Kroos MA, Vliet LV, Takeuchi H, Van der Ploeg AT, et al. (2007) Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II. Mol Genet Metab 90: 49-57.
66. Parenti G, Zuppaldi A, Gabriela Pittis M, Rosaria Tuzzi M, Annunziata I, et al. (2007) Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease. Mol Ther 15: 508-514.
67. Tropak MB, Reid SP, Guiral M, Withers SG, Mahuran D, (2004) Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients. J Biol Chem 279: 13478-13487.
68. Yu Z, Sawkar AR, Kelly JW, (2007) Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J 274: 4944-4950.
69. Ficko-Blean E, Stubbs KA, Nemirovsky O, Vocadlo DJ, Boraston AB, (2008) Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB. Proc Natl Acad Sci U S A 105: 6560-6565.
70. Lu J, Yang C, Chen M, Ye DY, Lonser RR, et al. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America 108: 21200-21205.
71. Wang F, Agnello G, Sotolongo N, Segatori L, (2011) Ca2+ homeostasis modulation enhances the amenability of L444P glucosylcerebrosidase to proteostasis regulation in patient-derived fibroblasts. ACS chemical biology 6: 158-168.
72. Wang F, Chou A, Segatori L, (2011) Lacidipine remodels protein folding and Ca 2+ homeostasis in Gaucher's disease fibroblasts: a mechanism to rescue mutant glucocerebrosidase. Chemistry & biology 18: 766-776.
73. Shen D, Wang X, Li X, Zhang X, Yao Z, et al. (2012) Lipid storage disorders block lysosomal trafficking by inhibiting a TRP channel and lysosomal calcium release. Nature communications 3: 731.
74. Yu T, Chung C, Shen D, Xu H, Lieberman AP, (2012) Ryanodine receptor antagonists adapt NPC1 proteostasis to ameliorate lipid storage in Niemann-Pick type C disease fibroblasts. Human molecular genetics 21: 3205-3214.
75. Lachmann R, (2010) Treatments for lysosomal storage disorders. Biochemical Society transactions 38: 1465-1468.
76. Beck M, (2010) Therapy for lysosomal storage disorders. IUBMB life 62: 33-40.
77. Porto C, Cardone M, Fontana F, Rossi B, Tuzzi MR, et al. (2009) The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts. Molecular therapy: the journal of the American Society of Gene Therapy 17: 964-971.
78. Porto C, Pisani A, Rosa M, Acampora E, Avolio V, et al. (2012) Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease. Journal of inherited metabolic disease 35: 513-520.
79. Futerman AH, van Meer G, (2004) The cell biology of lysosomal storage disorders. Nature reviews Molecular cell biology 5: 554-565.
80. Sands MS, Davidson BL, (2006) Gene therapy for lysosomal storage diseases. Molecular therapy: the journal of the American Society of Gene Therapy 13: 839-849.